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The original report published in 2001 on a possible association between maternal use of loratadine and an increased 
risk of infant hypospadias, based on data in the Swedish Medical Birth Register 1995-2001, has been followed up by 
continued surveillance in the same register. The original “signal” was based on 15 infants with hypospadias among 
2780 loratadine-exposed infants born, representing an adjusted odd ratio of about 2.3, statistically significant. Since 
then another 10 cases have been identified, and 12.5 expected. For the period 2001-2004, another 1911 loratadine-
exposed infants have been identified and only two had hypospadias (4 expected). Our present position is that the 
primary finding was a “signal” which had occurred by chance and the follow-up agrees with independent studies 
which indicate an absence of an association. This illustrates the care with which apparent statistically significant 
increases have to be handled when no prior hypothesis exists. 
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1.  Introduction 
In a recent issue of International Journal of Medical 
Sciences, a study was published based on a prescription 
register in Denmark which indicated an absence of an 
association between maternal use of loratadine and an 
increased risk for hypospadias in the offspring [1]. The 
reason for that study was a report we wrote [2] which 
described a system for an ongoing monitoring of 
maternal drug use and infant congenital malformations. 
As an example we presented the finding that maternal 
use of loratadine in early pregnancy was associated with 
a roughly doubled risk for infant hypospadias. We 
concluded: “The finding can still be random, but 
causality cannot be dismissed, even though the 
mechanism of action is not understood”. 
A reason for publishing a finding of this type is of 
course to encourage other scientists to look at their data 
sources to evaluate if the finding is supported or 
contradicted. Two small studies were published [3,4] 
which showed no such association but both were 
underpowered (210 and 161 women, respectively) and a 
study from CDC, using data from the National Birth 
Defects Prevention Study [5], found no association in a 
retrospective case-control study of 563 infants with 
hypospadias and 1444 male controls. 
The finding also caused two experimental studies: 
one performed by the drug company and using rats [6] 
which was negative and one [7] using mice which was 
positive. 
A further possibility to evaluate the assumed 
association is the continue surveillance in the original 
system. This we have done and present here the results. 
2.  Materials and Methods 
Our study is – like our previous study - based on the 
nationwide Swedish Medical Birth Register which 
contains information on maternal use of drug as reported 
and registered in early pregnancy [2, 8]. This information 
is based on interviews performed by midwifes and the 
system has been working since July 1, 1994 which makes 
it possible to collect a large number of pregnancies where 
the women used a drug (prescription or over-the counter) 
and to study offspring for various characteristics, 
including congenital malformations. Outcome is based on 
the recording of the attending paediatrician. It is known 
that for rather mild malformations like hypospadias, 
recording in the Medical Birth Register is incomplete. In 
our previous study we supplemented the information 
with data from the Swedish Register of Congenital 
Malformations, a surveillance register to which cases of 
hypospadias would be reported – before 1999 only cases 
with the urethral orifice in or behind the coronary sulcus. 
In the present study, data from the Hospital Discharge 
Register have been added. This register contains 
discharge diagnoses from all inpatient care in the country. 
Children with hypospadias will therefore be identified 
also when they, perhaps years after birth, undergo 
reconstructive surgery. A description of the system of 
ascertainment of malformed infants from various sources 
is available [9]. 
We previously studied births up to and including 
2001. We now supplemented those data with cases more 
recently identified (from the Hospital Discharge Register) 
and made a new study of births during 2002-2004. 
Risks were estimated as risk ratios (RR) with exact 
95% confidence intervals (95% CI) from exact Poisson 
distributions. RR was determined as the observed 
number of cases divided with the expected number, 
calculated from the total population after adjustment for 
year of birth, maternal age, parity, and smoking in early 
pregnancy. 
3.  Results 
In the repeated analysis of the first period (up to and 
including 2001) we restricted births to those occurring Int. J. Med. Sci. 2006, 3 
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after July 1, 1995 and searched the registers for all known 
cases of hypospadias. The total number of loratadine-
exposed infants is then 2780 and 25 had hypospadias 
identified (0.9%) - ten of the cases were thus ascertained 
from the Hospital Discharge Register after the neonatal 
period. The expected number is 12.5 and RR = 2.0 (95% CI 
1.29-2.95). The risk is slightly but not significantly lower 
than that given in our first study (RR =2.39, 95% CI 1.43-
3.38). 
For the period 2002-2004 (inclusive), we identified 
1911 infants exposed to loratadine – only two had 
hypospadias. The expected number, calculated as above, 
was 4.3 and RR = 0.47 with a 95% CI 0.06-1.68).  
The rates of hypospadias during the two 
observation periods (25 among 2780, 2 among 1911) are 
highly significant different (p<0.001).  
For the total observation period there were thus 27 
cases with an expected number of 16.8, RR = 1.61, 95%CI 
1.04-2.34). 
4.  Discussion. 
This is a typical situation which arises in any kind of 
surveillance: a clear-cut “signal” appears which is 
formally statistically significant. As there is no prior 
hypothesis and at the surveillance process we study a 
large number of “exposures” (in this case drugs) and 
many outcomes (in this case different types of congenital 
m a l f o r m a t i o n s )  i t  i s  t o  b e  e x p e c t e d  t h a t  a  n u m b e r  o f  
apparently significant associations will occur. In this 
situation there are a number of problems: to publish or 
not to publish and also how such a finding should be 
handled by authorities. 
If such a “signal” is published it is imperative to 
stress that in spite of formal statistical significance, the 
finding may be random and the reason for publishing is 
of course to ask other researchers to look for the presence 
or absence of that specific association. It is often thought 
that if there is a biological plausibility in the finding or if 
it can be repeated in animal experiments, it is more likely 
to be true. It should be remembered, however, that there 
was no biological plausibility when thalidomide was 
detected as a human teratogen, and animal experiments 
may be difficult to interpret. In the case of loratadine, 
both negative and positive animal findings have been 
published [6, 7].  
New studies from independent materials are the 
first option. When a very strong teratogenic effect is 
expected it may be relatively easy to verify or reject an 
observation. When the “signal” refers to a rather weak 
effect (a 2-3 times increase in risk) and the exposure rate 
is not very high as was the case with loratadine, it may be 
very difficult to identify materials large enough and of 
enough quality to get meaningful information. In the 
example of loratadine and hypospadias, two very small 
studies [3, 4] which were anyway published had in fact 
no power whatever to detect the assumed effect of 
loratadine, and a larger retrospective case-control study 
[5] was restricted to relatively severe cases and used 
retrospective data on drug exposure. The most recent 
study [1] was based on prescription data and therefore 
uncertain exposure information and in spite of its size of 
319 hypospadias cases found an adjusted OR for 
hypospadias after loratadine exposure during the first 
trimester with an upper confidence limit of 10.5. The 
authors calculate that in order to rule out a doubling of 
the risk, they would need a more than four times larger 
material. 
The next strategy, which is the basis of the present 
study, is continued surveillance. This necessitates the 
presence of an ongoing surveillance system which is the 
case with the Swedish Medical Birth Register. The follow-
up performed gave no evidence for an association 
between maternal use of loratadine and hypospadias and 
the rate of hypospadias among loratadine-exposed 
infants was highly significantly lower than that during 
the first period. There are two possible explanations. The 
noticed effect of loratadine during the first period could 
be the result of a synergism with an unknown factor – a 
search for such a factor has yielded no likely candidate. 
The second possibility, which is much more probable, is 
that the first “signal” was the result of multiple testing 
and was therefore not repeated at follow-up. 
5.  Conclusion 
Present evidence suggests that the earlier observed 
association between maternal use of loratadine in early 
pregnancy and birth of infants with hypospadias was the 
result of multiple testing. 
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